1-methyl-3-isobutylxanthine has been researched along with eg 626 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bristol, JA; Cain, MH; Weishaar, RE | 1 |
Azuma, H; Ishikawa, M; Takashima, Y; Yamakado, T | 1 |
1 review(s) available for 1-methyl-3-isobutylxanthine and eg 626
Article | Year |
---|---|
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; Calmodulin; Cardiotonic Agents; Guinea Pigs; Humans; Hypersensitivity; In Vitro Techniques; Lung Diseases; Myocardium; Platelet Aggregation; Substrate Specificity | 1985 |
1 other study(ies) available for 1-methyl-3-isobutylxanthine and eg 626
Article | Year |
---|---|
Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Adenosine Deaminase Inhibitors; Adenylyl Cyclases; Coformycin; Collagen; Cyclic AMP; Drug Synergism; Humans; In Vitro Techniques; Male; Pentostatin; Phosphodiesterase Inhibitors; Phthalazines; Platelet Aggregation; Pyridazines | 1984 |